APrevent and hearLIFE Group signed the exclusive distribution agreement
APrevent announced on 17TH December that APrevent and hearLIFE signed the exclusive distribution agreement for APrevent® VOIS in Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Cambodia, Laos, Myanmar and Brunei. We are going to provide patients with glottic insufficiency/unilateral vocal fold paralysis an innovative, safe and effective surgical treatment.
hearLIFE Group has a wealth of professional experience in Korea and Southeast Asia and are familiar with product registration process and ENT channels in regions. APrevent cooperates with hearLIFE group to expand market and sell APrevent® VOIS to the Korea and southeast Asia.
We expect to receive product license and launch market in southeast Asia in Q2 of 2021 and receive product license and launch market in Korea in Q3 of 2022.
APrevent® VOIS is characterized by its unique design for medialization thyroplasty. The goal is to get optimized results with reduced complications and revision rates. It is the first implant in the market that can be adjusted both intra- and postoperatively. Follow up procedures can be easily performed. The particular shape and unique design of the implant enables a precise adjustment of VOIS , improving voice quality, swallowing and preventing complications from glottic insufficiency. The implant materials are biocompatible medical grade silicone and titanium and can be implanted through a minimal invasive and standardized procedure, the latteralleviating pain and shortening of recovery time. Postoperative implant adjustments make it possible to optimize individual needs without revision surgery.